# SKYBIOTECH (NSE: SKYBIOTECH) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SKYBIOTECH · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹37 Cr, it ranks 3268th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Capital Goods sector; its industry is Conglomerates.

Its return on equity was −14.0% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2 Cr (+79.4% year on year) and net profit −₹0 Cr, on a consolidated basis. Promoters held 63.48% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹37 Cr |
| ROE | −14.0% (FY26) |
| ROCE | −9.4% (FY26) |
| Debt to equity | 1.05 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹2 Cr | +79.4% | −₹0 Cr | — | −₹2.96 |
| Q3 FY26 | ₹1 Cr | −61.9% | −₹0 Cr | — | −₹2.53 |
| Q2 FY26 | ₹2 Cr | +20.0% | −₹0 Cr | — | −₹1.29 |
| Q1 FY26 | ₹2 Cr | +25.1% | −₹0 Cr | — | ₹0.25 |
| Q4 FY25 | ₹1 Cr | — | −₹1 Cr | — | −₹13.68 |
| Q3 FY25 | ₹3 Cr | — | −₹0 Cr | −136.4% | −₹3.06 |
| Q2 FY25 | ₹2 Cr | — | −₹0 Cr | — | −₹5.46 |
| Q1 FY25 | ₹2 Cr | — | −₹1 Cr | — | −₹3.36 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | ₹0 Cr |
| FY24 | ₹0 Cr | ₹2 Cr |
| FY23 | ₹0 Cr | −₹0 Cr |
| FY22 | ₹0 Cr | −₹0 Cr |
| FY21 | ₹0 Cr | −₹0 Cr |
| FY20 | ₹0 Cr | −₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 63.48%
- Non-institutions: 36.52%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Share Samadhan](https://app.pivotnow.in/stock/SSL) | — | ₹39 Cr | — | — |
| [Storage Technol](https://app.pivotnow.in/stock/STAL) | — | ₹39 Cr | — | — |
| [Evans Electric](https://app.pivotnow.in/stock/EVANS) | — | ₹37 Cr | — | — |
| [Landmark Global](https://app.pivotnow.in/stock/LGLL) | — | ₹37 Cr | — | — |
| [Shreeshay Engin](https://app.pivotnow.in/stock/SHREESHAY) | — | ₹36 Cr | — | — |
| [Swastika Castal](https://app.pivotnow.in/stock/SWASTIKAAL) | — | ₹35 Cr | — | — |

## Questions and answers

### What is the market cap of SKYBIOTECH?

SKYBIOTECH's market capitalisation is ₹37 Cr (₹37 Cr) at the 19 Oct 2026 close, ranking 3268th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of SKYBIOTECH?

Return on equity was −14.0% in FY26 and return on capital employed was −9.4% in FY26 (consolidated figures).

### Is SKYBIOTECH a debt-free company?

No. SKYBIOTECH's debt-to-equity ratio was 1.05 in FY26, with total debt of ₹8 Cr.

### What were SKYBIOTECH's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), SKYBIOTECH reported revenue of ₹2 Cr, +79.4% year on year, and net profit of −₹0 Cr.

### What is the shareholding pattern of SKYBIOTECH?

As of 30 Jun 2026: promoters 63.48%, non-institutions 36.52%.

### Who are SKYBIOTECH's competitors?

The listed Capital Goods companies closest to SKYBIOTECH by market cap are Share Samadhan, Storage Technol, Evans Electric, Landmark Global, Shreeshay Engin and Swastika Castal.

### Is SKYBIOTECH a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out SKYBIOTECH's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SKYBIOTECH against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.